Neurofibromatosis Type 2 (NF2) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Neurofibromatosis Type 2 (NF2) Market Outlook
Thelansis’s “Neurofibromatosis Type 2
(NF2) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Neurofibromatosis Type 2 (NF2)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Neurofibromatosis
Type 2 (NF2) Overview
Neurofibromatosis
type 2 (NF2) is an autosomal-dominant tumor-prone disorder predisposed to nerve
system tumors. Bilateral vestibular schwannoma (VS) is pathognomonic or the
disease, whereas schwannoma at other locations, meningiomas, ependymomas, and
early onset lenticular opacities are frequently associated with the phenotypes.
Vestibular schwannoma-related symptoms were seen in most of the patients (55%),
followed by ophthalmological symptoms/abnormalities (45%) and cutaneous
features (38%). About 40% of all patients were monosymptomatic, 55% showed ≥2
symptoms at symptom onset, and ~5% were asymptomatic. Including polysymptomatic
occurrence and symptomatic and asymptomatic findings, 62% of young patients
exhibit ophthalmological abnormalities, followed by cutaneous findings (43%).
Most people with NF2 develop symptoms in the late teen and early adult years,
although about 10% of people develop symptoms during late childhood. The most
common symptoms of NF2 include ringing in the ears (tinnitus), gradual hearing
loss, and balance problems.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment